REFERENCES
(2018). Global, regional, and national incidence, prevalence, and years
lived with disability for 354 diseases and injuries for 195 countries
and territories, 1990-2017: a systematic analysis for the Global Burden
of Disease Study 2017. Lancet (London, England) 392: 1789-1858.
Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning
PJ, et al. (2013). Magnetic resonance angiography of intracranial
and extracranial arteries in patients with spontaneous migraine without
aura: a cross-sectional study. Lancet Neurol 12: 454-461.
Amrutkar DV, Ploug KB, Hay-Schmidt A, Porreca F, Olesen J, &
Jansen-Olesen I (2012). mRNA expression of 5-hydroxytryptamine 1B, 1D,
and 1F receptors and their role in controlling the release of calcitonin
gene-related peptide in the rat trigeminovascular system. Pain
153: 830-838.
Ashina M, Hansen JM, BO AD, & Olesen J (2017). Human models of migraine
- short-term pain for long-term gain. Nat Rev Neurol 13:713-724.
Ashina MD, D. Bonner, JH et al (2019) A phase 2, randomized,
double-blind, placebo-controlled study to evaluate the efficacy and
safety of AMG 301 in migraine prevention. . vol. Athens.
Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, & Mackenzie KD
(2021). Migraine therapeutics differentially modulate the CGRP pathway.
Cephalalgia: 0333102420983282.
Bower RL, Eftekhari S, Waldvogel HJ, Faull RL, Tajti J, Edvinsson
L, et al. (2016). Mapping the calcitonin receptor in human brain
stem. Am J Physiol Regul Integr Comp Physiol 310: R788-793.
Charles A, & Pozo-Rosich P (2019). Targeting calcitonin gene-related
peptide: a new era in migraine therapy. Lancet (London, England)
394: 1765-1774.
Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, & Reid KB (1987).
Purification and characterization of a peptide from amyloid-rich
pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A
84: 8628-8632.
Edvinsson JCA, Warfvinge K, Krause DN, Blixt FW, Sheykhzade M, Edvinsson
L, et al. (2019). C-fibers may modulate adjacent Adelta-fibers
through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal
system. J Headache Pain 20: 105.
Edvinsson L (2011). Tracing neural connections to pain pathways with
relevance to primary headaches. Cephalalgia 31: 737-747.
Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, et
al. (2002). Effect of the CGRP receptor antagonist BIBN4096BS in human
cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J
Pharmacol 434: 49-53.
Edvinsson L, Chan KY, Eftekhari S, Nilsson E, de Vries R, Saveland
H, et al. (2010). Effect of the calcitonin gene-related peptide
(CGRP) receptor antagonist telcagepant in human cranial arteries.
Cephalalgia 30: 1233-1240.
Edvinsson L, Ekman R, Jansen I, McCulloch J, & Uddman R (1987).
Calcitonin gene-related peptide and cerebral blood vessels: distribution
and vasomotor effects. J Cereb Blood Flow Metab 7: 720-728.
Edvinsson L, Fredholm BB, Hamel E, Jansen I, & Verrecchia C (1985).
Perivascular peptides relax cerebral arteries concomitant with
stimulation of cyclic adenosine monophosphate accumulation or release of
an endothelium-derived relaxing factor in the cat. Neurosci Lett
58: 213-217.
Edvinsson L, Goadsby PJ, & Uddman R (2001). Amylin: localization,
effects on cerebral arteries and on local cerebral blood flow in the
cat. ScientificWorldJournal 1: 168-180.
Edvinsson L, Grell AS, & Warfvinge K (2020). Expression of the CGRP
Family of Neuropeptides and their Receptors in the Trigeminal Ganglion.
J Mol Neurosci 70: 930-944.
Edvinsson L, Haanes KA, & Warfvinge K (2019). Does inflammation have a
role in migraine? Nat Rev Neurol 15: 483-490.
Edvinsson L, Haanes KA, Warfvinge K, & Krause DN (2018). CGRP as the
target of new migraine therapies - successful translation from bench to
clinic. Nat Rev Neurol 14: 338-350.
Edvinsson L, Nilsson E, & Jansen-Olesen I (2007). Inhibitory effect of
BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP
induced vasodilatation in the perfused and non-perfused rat middle
cerebral artery. Br J Pharmacol 150: 633-640.
Eftekhari S, Gaspar RC, Roberts R, Chen TB, Zeng Z, Villarreal S,
et al. (2016). Localization of CGRP receptor components and receptor
binding sites in rhesus monkey brainstem: A detailed study using in situ
hybridization, immunofluorescence, and autoradiography. J Comp Neurol
524: 90-118.
Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, & Edvinsson L
(2010). Differential distribution of calcitonin gene-related peptide and
its receptor components in the human trigeminal ganglion. Neuroscience
169: 683-696.
Eftekhari S, Salvatore CA, Johansson S, Chen TB, Zeng Z, & Edvinsson L
(2015). Localization of CGRP, CGRP receptor, PACAP and glutamate in
trigeminal ganglion. Relation to the blood-brain barrier. Brain Res
1600: 93-109.
Eftekhari S, Warfvinge K, Blixt FW, & Edvinsson L (2013).
Differentiation of nerve fibers storing CGRP and CGRP receptors in the
peripheral trigeminovascular system. J Pain 14: 1289-1303.
Erdling A, Sheykhzade M, & Edvinsson L (2017). Differential inhibitory
response to telcagepant on alphaCGRP induced vasorelaxation and
intracellular Ca2+ levels in the perfused and non-perfused isolated rat
middle cerebral artery. J Headache Pain 18: 61.
Ferrero H, Larrayoz IM, Gil-Bea FJ, Martinez A, & Ramirez MJ (2018).
Adrenomedullin, a Novel Target for Neurodegenerative Diseases. Mol
Neurobiol.
Ferrero H, Larrayoz IM, Martisova E, Solas M, Howlett DR, Francis
PT, et al. (2018). Increased Levels of Brain Adrenomedullin in
the Neuropathology of Alzheimer’s Disease. Mol Neurobiol 55:5177-5183.
Findlay DM, & Sexton PM (2004). Calcitonin. Growth Factors 22:217-224.
Fontaine D, Almairac F, Santucci S, Fernandez C, Dallel R, Pallud
J, et al. (2018). Dural and pial pain-sensitive structures in
humans: new inputs from awake craniotomies. Brain 141:1040-1048.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators
(2017). Global, regional, and national incidence, prevalence, and years
lived with disability for 328 diseases and injuries for 195 countries,
1990-2016: a systematic analysis for the Global Burden of Disease Study
2016. Lancet (London, England) 390: 1211-1259.
Gingell JJ, Hendrikse ER, & Hay DL (2019). New Insights into the
Regulation of CGRP-Family Receptors. Trends Pharmacol Sci 40:71-83.
Goadsby PJ, & Akerman S (2012). The trigeminovascular system does not
require a peripheral sensory input to be activated–migraine is a
central disorder. Focus on ’Effect of cortical spreading depression on
basal and evoked traffic in the trigeminovascular sensory system’.
Cephalalgia 32: 3-5.
Goadsby PJ, & Edvinsson L (1994). Joint 1994 Wolff Award Presentation.
Peripheral and central trigeminovascular activation in cat is blocked by
the serotonin (5HT)-1D receptor agonist 311C90. Headache 34:394-399.
Goadsby PJ, Edvinsson L, & Ekman R (1988). Release of vasoactive
peptides in the extracerebral circulation of humans and the cat during
activation of the trigeminovascular system. Ann Neurol 23:193-196.
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, &
Akerman S (2017). Pathophysiology of Migraine: A Disorder of Sensory
Processing. Physiol Rev 97: 553-622.
Goadsby PJ, & Knight YE (1997). Direct evidence for central sites of
action of zolmitriptan (311C90): an autoradiographic study in cat.
Cephalalgia 17: 153-158.
Hadjikhani N, Albrecht DS, Mainero C, Ichijo E, Ward N, Granziera
C, et al. (2020). Extra-Axial Inflammatory Signal in Parameninges
in Migraine with Visual Aura. Ann Neurol 87: 939-949.
Hay DL (2017). Amylin. Headache 57 Suppl 2: 89-96.
Hay DL, Garelja ML, Poyner DR, & Walker CS (2018). Update on the
pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br
J Pharmacol 175: 3-17.
Hay DL, Harris PW, Kowalczyk R, Brimble MA, Rathbone DL, Barwell
J, et al. (2014). Structure-activity relationships of the
N-terminus of calcitonin gene-related peptide: key roles of alanine-5
and threonine-6 in receptor activation. Br J Pharmacol 171:415-426.
Hay DL, & Pioszak AA (2016). Receptor Activity-Modifying Proteins
(RAMPs): New Insights and Roles. Annu Rev Pharmacol Toxicol 56:469-487.
Hendrikse ER, Bower RL, Hay DL, & Walker CS (2018). Molecular studies
of CGRP and the CGRP family of peptides in the central nervous system.
Cephalalgia: 333102418765787.
Ho TW, Edvinsson L, & Goadsby PJ (2010). CGRP and its receptors provide
new insights into migraine pathophysiology. Nat Rev Neurol 6:573-582.
Hoffmann J, Wecker S, Neeb L, Dirnagl U, & Reuter U (2012). Primary
trigeminal afferents are the main source for stimulus-induced CGRP
release into jugular vein blood and CSF. Cephalalgia 32:659-667.
Irimia P, Martínez-Valbuena I, Mínguez-Olaondo A, Domínguez-Vivero C,
Sánchez-Arias J-A, Martínez-Vila E, et al. Interictal amylin
levels in chronic migraine patients: A case-control study. Cephalalgia
0: 0333102420977106.
Johnson KW, Morin SM, Wroblewski VJ, & Johnson MP (2019). Peripheral
and central nervous system distribution of the CGRP neutralizing
antibody [(125)I] galcanezumab in male rats. Cephalalgia
39: 1241-1248.
Juhl L, Petersen KA, Larsen EH, Jansen-Olesen I, & Olesen J (2006). The
in vivo effect of adrenomedullin on rat dural and pial arteries. Eur J
Pharmacol 538: 101-107.
Khan S, Amin FM, Fliedner FP, Christensen CE, Tolnai D, Younis S,
et al. (2019). Investigating macrophage-mediated inflammation in
migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T
magnetic resonance imaging. Cephalalgia 39: 1407-1420.
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H,
et al. (1993). Adrenomedullin: a novel hypotensive peptide isolated
from human pheochromocytoma. Biochem Biophys Res Commun 192:553-560.
Labastida-Ramirez A, Rubio-Beltran E, Haanes KA, Chan KY, Garrelds IM,
Johnson KW, et al. (2020). Lasmiditan inhibits calcitonin
gene-related peptide release in the rodent trigeminovascular system.
Pain 161: 1092-1099.
Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF,
et al. (2008). Calcitonin receptor-like receptor (CLR), receptor
activity-modifying protein 1 (RAMP1), and calcitonin gene-related
peptide (CGRP) immunoreactivity in the rat trigeminovascular system:
differences between peripheral and central CGRP receptor distribution. J
Comp Neurol 507: 1277-1299.
Levy D, Burstein R, & Strassman AM (2005). Calcitonin gene-related
peptide does not excite or sensitize meningeal nociceptors: implications
for the pathophysiology of migraine. Ann Neurol 58: 698-705.
Lundblad C, Haanes KA, Grande G, & Edvinsson L (2015). Experimental
inflammation following dural application of complete Freund’s adjuvant
or inflammatory soup does not alter brain and trigeminal microvascular
passage. J Headache Pain 16: 91.
May A (2017). Understanding migraine as a cycling brain syndrome:
reviewing the evidence from functional imaging. Neurol Sci 38:125-130.
May A, & Burstein R (2019). Hypothalamic regulation of headache and
migraine. Cephalalgia: 333102419867280.
McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et
al. (1998). RAMPs regulate the transport and ligand specificity of the
calcitonin-receptor-like receptor. Nature 393: 333-339.
Messlinger K, Balcziak LK, & Russo AF (2020). Cross-talk signaling in
the trigeminal ganglion: role of neuropeptides and other mediators.
Journal of Neural Transmission 127: 431-444.
Messlinger K, & Russo AF (2019). Current understanding of trigeminal
ganglion structure and function in headache. Cephalalgia 39:1661-1674.
Mietlicki-Baase EG, McGrath LE, Koch-Laskowski K, Krawczyk J, Reiner DJ,
Pham T, et al. (2017). Amylin receptor activation in the ventral
tegmental area reduces motivated ingestive behavior. Neuropharmacology
123: 67-79.
Miller S, Liu H, Warfvinge K, Shi L, Dovlatyan M, Xu C, et al.(2016). Immunohistochemical localization of the calcitonin gene-related
peptide binding site in the primate trigeminovascular system using
functional antagonist antibodies. Neuroscience 328: 165-183.
Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, Sugimoto K, et
al. (2020). Anti-migraine Calcitonin Gene-Related Peptide Receptor
Antagonists Worsen Cerebral Ischemic Outcome in Mice. Ann Neurol
88: 771-784.
Murinson BB, & Griffin JW (2004). C-fiber structure varies with
location in peripheral nerve. Journal of Neuropathology & Experimental
Neurology 63: 246-254.
Noseda R, Schain AJ, Melo-Carrillo A, Tien J, Stratton J, Mai F,
et al. (2020). Fluorescently-labeled fremanezumab is distributed to
sensory and autonomic ganglia and the dura but not to the brain of rats
with uncompromised blood brain barrier. Cephalalgia 40:229-240.
Ohlsson L, Haanes KA, Kronvall E, Xu C, Snellman J, & Edvinsson L
(2019). Erenumab (AMG 334), a monoclonal antagonist antibody against the
canonical CGRP receptor, does not impair vasodilatory or contractile
responses to other vasoactive agents in human isolated cranial arteries.
Cephalalgia 39: 1745-1752.
Ohlsson L, Kronvall E, Stratton J, & Edvinsson L (2018). Fremanezumab
blocks CGRP induced dilatation in human cerebral, middle meningeal and
abdominal arteries. J Headache Pain 19: 66.
Oliver KR, Wainwright A, Edvinsson L, Pickard JD, & Hill RG (2002).
Immunohistochemical localization of calcitonin receptor-like receptor
and receptor activity-modifying proteins in the human cerebral
vasculature. J Cereb Blood Flow Metab 22: 620-629.
Pietrobon D, & Moskowitz MA (2013). Pathophysiology of migraine. Annu
Rev Physiol 75: 365-391.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, et
al. (2002). International Union of Pharmacology. XXXII. The mammalian
calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin
receptors. Pharmacol Rev 54: 233-246.
Rubio-Beltran E, Chan KY, Danser AJ, MaassenVanDenBrink A, & Edvinsson
L (2020). Characterisation of the calcitonin gene-related peptide
receptor antagonists ubrogepant and atogepant in human isolated
coronary, cerebral and middle meningeal arteries. Cephalalgia
40: 357-366.
Satoh F, Takahashi K, Murakami O, Totsune K, Sone M, Ohneda M, et
al. (1996). Immunocytochemical localization of adrenomedullin-like
immunoreactivity in the human hypothalamus and the adrenal gland.
Neurosci Lett 203: 207-210.
Saxena PR, & Den Boer MO (1991). Pharmacology of antimigraine drugs. J
Neurol 238 Suppl 1: S28-35.
Schain AJ, Melo-Carrillo A, Stratton J, Strassman AM, & Burstein R
(2019). CSD-Induced Arterial Dilatation and Plasma Protein Extravasation
Are Unaffected by Fremanezumab: Implications for CGRP’s Role in Migraine
with Aura. J Neurosci 39: 6001-6011.
Schulte LH, & May A (2017). Of generators, networks and migraine
attacks. Curr Opin Neurol 30: 241-245.
Schulte LH, Mehnert J, & May A (2020). Longitudinal Neuroimaging over
30 Days: Temporal Characteristics of Migraine. Ann Neurol 87:646-651.
Schulte LH, Menz MM, Haaker J, & May A (2020). The migraineur’s brain
networks: Continuous resting state fMRI over 30 days. Cephalalgia
40: 1614-1621.
Schultz N, Byman E, Fex M, & Wennstrom M (2017). Amylin alters human
brain pericyte viability and NG2 expression. J Cereb Blood Flow Metab
37: 1470-1482.
Serrano J, Uttenthal LO, Martinez A, Fernandez AP, Martinez de Velasco
J, Alonso D, et al. (2000). Distribution of adrenomedullin-like
immunoreactivity in the rat central nervous system by light and electron
microscopy. Brain Res 853: 245-268.
Walker CS, Eftekhari S, Bower RL, Wilderman A, Insel PA, Edvinsson
L, et al. (2015). A second trigeminal CGRP receptor: function and
expression of the AMY1 receptor. Ann Clin Transl Neurol 2:595-608.